Connect with us

Announcements

Tilray (TLRY) Will Now Export Medical Marijuana from Portugal to Germany for Cannamedical

Andrew Taft

Published

on

Tilray (TLRY) Will Now Export Medical Marijuana from Portugal to Germany for Cannamedical

Today, Tilray Inc. has announced another European deal through its subsidiary Tilray Portugal.

This is part of the company’s efforts to diversify internationally as legalization in Canada fails to see a surge in revenue.

Tilray’s Portuguese arm inked a contract to supply German consumers a wholesale shipment of medicinal marijuana to Cannamedical Pharma GmbH. Cannamedical has a license to supply cannabis to patients via a network of 2,500 clinics and pharmacies nationally.

According to the agreement, over $3 million worth of medicinal grade marijuana will be exported from Portugal to Germany later this fall. This will mark the initial major shipment from the company’s newly-opened Cantanhede campus.

The site was given GMP certification earlier this summer, and has been host to an array of local political figures who tour the facility as employment drive causes worker hiring by Tilray Portugal triple in digits.

Brendan Kennedy, the Chief Executive Officer of Tilray, stated that his team believes the 2.5 million square feet of cultivation and Europe’s processing space will help at cutting down costs and improve profit margins while hedging against risks related to regulation.

Besides the indoor growing facility, Tilray recently leased twenty hectares of outdoor growing space in Portugal’s Alentejo area to ramp production efforts further. Cannabis grown in this outdoor space will then be shipped to the Portuguese campus to be processed, packaged, and distributed to European customers.

Europe is not Tilray’s focus market for international expansion. In the recent month, the company has been importing Cannabidiol (CBD) capsules to the southern border to the United States for new clinical trials.

Several clinical studies and major research projects on the effectiveness of CBD are now underway in the U.S. as the FDA is expected to come up with more strict regulations as the product gains more popularity.

Andrew is a full-time professional writer in Canada with over 8 years of esteemed experience. He is one of the best cannabis health researchers, polished legal investigators and active CBD news reporters we have at TOC. While being featured in hundreds of health, technology, science, and even bitcoin publications; Andrew's now on the frontline of the Canadian cannabis culture and will continue breaking down everything so easily your grandma can understand hemp and CBD.

Advertisement
Advertisement

Follow Times of CBD News

popular-cbd-health-benefits best-cannabidiol-guide-resources hemp guide

TimesofCBD.com is the most active daily cannabis news publication online inviting all readers to come for the headlines and stay for the insights. The primary focus is on curating latest CBD news updates, marijuana market movements and researched hemp-based product user guides. While everything is here for educational, informational purposes only, quality is always the priority and fact checking sources with industry-leading accuracy in reporting is at the top of the list of this emerging, innovative industry.

Note: Always seek real additional medical advice and consultation with a professional healthcare practitioner before considering any CBD. No statements found on this website have underwent Food and Drug Administration evaluation. The efficacy of any products or claims made have never been approved by the FDA either. No products shall ever be intended to diagnose, treat or cure any disease or prevent any ailment.

Got news? Email us [email protected]

Trending Cannabis News

Advertisement